In a report released today, Joseph France from Cantor Fitzgerald maintained a Buy rating on Sabra Healthcare REIT (NASDAQ: SBRA), with a price target of $25. The company’s shares opened today at $20.99.
France noted:
“We rate SBRA $25 price target, based on our expectations for the recently completed combination with CCP, portfolio repositioning, and divestitures, most of which we expect to be completed in 2018. SBRA has an attractive dividend yield of 10.8%, with the company paying out 75% of normalized AFFO. Valuation Summary We arrive at our price target of $25 via a blended average of fair values derived from our DCF model, price/AFFO multiple and Net Asset Value analysis.”
According to TipRanks.com, France is a 5-star analyst with an average return of 12.3% and a 59.6% success rate. France covers the Services sector, focusing on stocks such as Cross Country Healthcare, Five Star Quality Care, and US Physical Therapy.
Currently, the analyst consensus on Sabra Healthcare REIT is Moderate Buy and the average price target is $21.88, representing a 4.2% upside.
In a report issued on May 21, Raymond James also upgraded the stock to Buy.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.31 and a one-year low of $15.78. Currently, Sabra Healthcare REIT has an average volume of 1.73M.
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sabra Health Care REIT, Inc. engages in managing and investing in healthcare-related real estate properties. It focuses on the acquisition, financing, and owning real estate property to be leased to third party tenants in the healthcare sector. The company was founded on May 10, 2010 and is headquartered in Irvine, CA.
